Pdx Models

PDX models are important preclinical tools to develop effective and safe therapeutics that combat cancer. Drug developers can utilize PDX models to target patient tumors with specific oncogene profiles. Our PDX models are significantly more accurate in predicting clinical efficacy than other more conventional approaches. This predictive accuracy helps our clients develop successful drug candidates by providing a more accurate assessment of therapeutic efficacy, thereby saving our client companies time and resources.

With NexusPharma clients receive a boutique experience with highly skilled experts customized for their study.

Is this right for you? Contact us to speak with one of our experts to start building your study.

quote Request a Quote

Please register or login to view detailed model information

Please select a body part

Please select a Cancer


Cancer Select

    Head and Neck


    Lymph Nodes













    Rotary Select


    Our unique collections of patient-derived xenograft (PDX) models used to evaluate safety and efficacy include:

    • Pancreatic Ductal Adenocarcinoma (PDAC) Pancreatic Cancer PDX Collection - in vivo screening for drug efficacy, tumor kinetics and animal survival studies

    • Gastrointestinal (GI) PDX Collection (Esophageal, Gastric, Colorectal and liver cancer models) - histological analysis and SOC studies

    • Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung cancer (SCLC) and Mesothelioma PDX Collection - WES - mutational and RNA-seq gene expression analysis for model selection

    • Lymphoma PDX Collection – SOC studies, subcutaneous (SQ) and disseminating implantation studies

    • Bladder Cancer PDX Collection – application of PDX models for immune-oncology

    • Radiation Therapy Core –RT/drug combination studies with combinations of chemotherapies, targeted agents, and immune-oncology drugs with whole body and focal radiation therapy

    Custom Models

    NexusPharma offers to create PDX models based on the specific customer request. These models might be developed on exclusive and nonexclusive basis from primary and metastatic lesions with regard to patient ethnicity, medical history and treatment protocols.

    PDX Discovery Platform

    PDX models with established KRAS gene mutations

    PNX Model # Tumor Type Gene Name Protein Change DNA Change
    PNX0079 Endometrium KRAS p.G12V c.35G>T
    PNX0128 Endometrium KRAS p.Q61H c.183A>C
    PNX0285 Gastric KRAS p.G12D c.35G>A
    PNX0314 Rectum KRAS p.Q61H c.183A>T
    PNX0314 Rectum KRAS p.G13C c.37G>T
    PNX0419 Colon KRAS p.G13D c.38G>A
    PNX0435 Colon KRAS p.G12D c.35G>A
    PNX0001 Pancreatic KRAS p.G12V c.35G>T
    PNX0017 Pancreatic KRAS p.G12D c.35G>A
    PNX0045 Pancreatic KRAS p.G12D c.35G>A
    PNX0050 Pancreatic KRAS p.Q61H c.183A>C
    PNX0050 Pancreatic KRAS T58I c.173C>T
    PNX0055 Pancreatic KRAS p.G12D c.35G>A
    PNX0059 Pancreatic KRAS p.G12D c.35G>A
    PNX0060 Pancreatic KRAS p.G12D c.35G>A
    PNX0159 Pancreatic KRAS p.G12D c.35G>A
    PNX0167 Pancreatic KRAS G12R c.34G>C
    PNX0174 Pancreatic KRAS p.G12D c.35G>A
    PNX0175 Pancreatic KRAS G12R c.34G>C
    PNX0195 Pancreatic KRAS p.G12V c.35G>T
    PNX0197 Pancreatic KRAS p.G12D c.35G>A
    PNX0230 Pancreatic KRAS G12R c.34G>C
    PNX0278 Pancreatic KRAS p.G12D c.35G>A
    PNX0296 Pancreatic KRAS p.G12D c.35G>A
    PNX0302 Pancreatic KRAS p.G12D c.35G>A
    PNX0362 Pancreatic KRAS p.G12V c.35G>T
    • IRB 12-822
    • Patient-derived xenografts (PDX)
    • Xenopatient Trials of New Drugs
    • Active Drugs
    • Validation in GEM
    • Path to Clinical Trials

    Examples of Study Services

    • Two Mesothelioma PDX Models Formed Tumors in Humanized Mice

      huMice models provide an opportunity to investigate response to immuno-oncology agents 11 mesothelioma PDX models available
    • Two Lung NSCLC PDX Models in Humanized Mice

      Two NexusPharma Lung PDX models demonstrate sensitivity to the immuno-oncology agent pembrolizumab in humanized mice 5 Nexus Pharma Lung PDX models established tumor growth in huCD34 NCG mice
    • Two Bladder Cancer PDX Models in Humanized Mice

      Two NexusPharma Bladder PDX models demonstrate differential sensitivity to the immuno-oncology agent pembrolizumab and standard of care drug cisplatin in humanized mice 4 NexusPharma Bladder PDX models established tumor growth in huCD34 NCG mice
    • SOC Treatment in a Subset of Colon, Rectal, and Small Intestine PDX Models

      Strong correlation with patient responses to the treatment for all tested agents
    • RNASEQ analysis of differential gene expression in NexusPharma PDX models

      Biomarker analysis using gene expression data allows our clients to select the most relevant PDX models for their studies RNAseq data analysis available for 78 PDX models and next 21 models are in progress

      Genomic Analysis of PDX Models

      ANTRX1 Gene Expression In a Subset of PDX Models

      Relative mRNA Expression of ANTRXR1 in PDX Tumors

      ANTRX1 Gene Expression in Various Tumor Types

      mRNA Expression of ANTRX1 in Various Tumor Types

      Data Analysis

      over 150 PDX models established
      Validation with SOC

      (for selected model)

      Molecular Characterization
      IHC Targeted gene expression profiling Gene Mutation analysis by WES and NGS gene panels
      Patient Data